{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 99 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'participation in pulmonary', 'rehabilitation program within 45 days', 'prior to signing informed consent', 'Added sub bullet points to secondary', 'endpoint bullet # 3 to be consistent with', 'section 5.1.1.2.', 'Rationale for change', 'Administrative changes. Update the Inclusion', 'and Exclusion Criteria to further improve', 'recruiting opportunities.', 'Section to be changed', 'Flowchart', 'Description of change', 'Updated Footnote 6 to \"6 weeks\" from', '\"4 weeks\"', 'Rationale for change', 'To provide more clarification as to when', 'incremental cycle ergometry will be conducted.', 'To increase the window to schedule PR.', 'Section to be changed', '1.4', 'Description of change', 'Changed \"not less than three\" to \"up to', 'thirty\"', 'Added \"gastrointestinal perforation\"', 'Rationale for change', 'Updated to improve recruiting opportunities; to', 'align with current AESIs in the program.', 'Section to be changed', '2.1.1', 'Description of change', 'Changed \"for 3-30 mos\" to \"for up to 30 mos\"', 'Rationale for change', 'Updated to improve recruiting opportunities.', 'Section to be changed', '3.1', 'Description of change', 'Changed \"currently taking nintedanib at a dose', 'of 150 mg bid for not less than 3 months or', 'more than 30 months\" to \"treated with', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 100 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'nintedanib at a dose of 150 mg bid for up to 30', 'months.\"', 'Rationale for change', 'Updated to improve recruiting opportunities.', 'Section to be changed', '3.2', 'Description of change', 'Updated wording from \"The cohort in this', 'study is patients that are on a stable therapy', 'with nintedanib for 3- 30 months.\" to \"The', 'cohort in this study is patients that are treated', 'with nintedanib for up to 30 months.\"', 'Rationale for change', 'Updated to improve recruiting opportunities.', 'Section to be changed', '3.3.1', 'Description of change', 'Changed \"between 3 and 30 months\" to \"up to', '30 months\"', 'Rationale for change', 'Updated to improve recruiting opportunities.', 'Section to be changed', '3.3.2', 'Description of change', 'Changed \"Currently taking', 'nintedanib150 mg BID, at a stable dose', 'for 3-30 months\" to \"Patients being', 'treated with a stable dose of nintedanib', '150 mg BID for up to 30 months.', 'Patients who have recently started', 'nintedanib 150 mg BID and have started', 'by the day of randomization must be on', 'nintedanib 150 mg BID a minimum of 10', 'days by the first day of pulmonary', 'rehabilitation.\"', 'Removed footnote 2.', 'Changed \"FVC from > 50% of', 'predicted\" to 6> 45% of predicted\"', 'Change \"Physically capable of', 'performing both a 6 minute walk test', 'must successfully', 'complete the practice tests for both, per', 'the instructions. Potential sub-study', 'patients that require supplemental', 'oxygen or cannot complete the', 'incremental or practice work rate cycle', 'ergometry test will not participate in the', 'sub-study, but will qualify for the main', 'study.\" to \" Physically capable of', 'performing both a 6 minute walk test', 'and work rate cycle ergometry (sub-', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 101 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'study patients), must successfully', 'complete the practice tests for the 6', 'minute walk test, per the instructions.', 'Potential sub-study patients that require', 'supplemental oxygen or cannot complete', 'the incremental work rate cycle', 'ergometry test will not participate in the', 'sub-study, but will qualify for the main', 'study.\"', 'Rationale for change', 'Updated to improve recruiting opportunities.', 'Administrative change.', 'Section to be changed', '3.3.3', 'Description of change', 'Changed \"Participation in a pulmonary', 'rehabilitation program completed in the past 3', 'months.\" to \"Previous participation in', 'pulmonary rehabilitation program within 45', 'days prior to signing consent.\"', 'Rationale for change', 'Updated to improve recruiting opportunities.', 'Section to be changed', '4.1.2', 'Description of change', 'Changed \"for 3 to 30 months\" to \"for up', 'to 30 months to qualify for the trial and', 'to continue on nintedanib for the', 'duration of the trial. Patients who have', 'recently started nintedanib 150 mg BID', 'and have started by the day of', 'randomization must be on nintedanib', '150 mg BID a minimum of 10 days by', 'the first day of pulmonary', 'rehabilitation.\"', 'Added \"Temporary\" in front of dose.', 'Rationale for change', 'Updated to improve recruiting opportunities.', 'Administrative change.', 'Section to be changed', '4.1.4', 'Description of change', 'Changed \"Subjects are required to be on a', 'stable (3 to 30 months) dose of nintedanib 150', 'mg BID, administered per prescribing', 'instructions (R18-1289), to enter the trial and to', 'continue on this dose throughout the trial.\" to', '\"Subjects are required to be treated on a stable', '(up to 30 months) dose of nintedanib 150 mg', 'BID, administered per prescribing instructions', '(R18-1289), to enter the trial and to continue on', 'this dose throughout the trial. Patients who', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}